The Melanoma and Skin Cancer Steering Committee (MSCSC) addresses the design, prioritization, and evaluation of concepts for phase 2, 2/3, and 3 clinical trials in melanoma and skin cancer. Committee activities help foster collaboration between groups and institutions engaged in conducting trials. The MSCSC's membership comprises NCTN group representatives, community oncologists, Specialized Programs of Research Excellence (SPORE) representatives, biostatisticians, patient advocates, subject matter experts, and NCI staff.
Chair
Alexander Noor Shoushtari, M.D.
Memorial Sloan Kettering Cancer Center
Members
Carmen Allegra, M.D.
National Cancer Institute, CTEP
Marcus O. Butler, M.D.
University Health Network-Princess Margaret Cancer Centre
Gary C. Doolittle, M.D.
University of Kansas Cancer Center
Neil Gross, M.D., FACS
University of Texas M.D. Anderson Cancer Center
Tina J. Hieken, M.D.
Mayo Clinic
John Robert Hyngstrom, M.D.
Rush University Medical Center
Edward L. Korn, Ph.D.
National Cancer Institute
Nicole Kounalakis, M.D.
Northside Cancer Institute
Shlomo Koyfman, M.D.
Cleveland Clinic
Sandra Lee, Sc.D.
Dana-Farber Cancer Institute, Harvard University
Janice M. Mehnert, M.D.
NYU Langone Health
Margaret M. Mooney, M.D., M.B.A.
National Cancer Institute
Sapna Patel, M.D.
University of Colorado
Teresa Petrella, M.D., M.S.
Sunnybrook Health Sciences Centre
Chris Bradley White
Mucosal Melanoma Survivor LLc
Jedd D. Wolchok, M.D., Ph.D.
Weill Cornell Medicine
Michael C. Wu, Ph.D.
Fred Hutchinson Cancer Center
Hassane Zarour, M.D.
University of Pittsburgh
NCI CCCT Program Director
Elena Schwartz, Ph.D., M.S.
elena.schwartz@nih.gov